TalalHilalMD

Summary

• Talal Hilal, MD, is a hematologist specializing in hematologic oncology based in Phoenix, AZ. He completed his medical degree at the Royal College of Surgeons in Ireland - Medical University of Bahrain and his residency in Internal Medicine at the University of Kentucky College of Medicine. Dr. Hilal pursued a fellowship in Hematology and Medical Oncology at the Mayo Clinic College of Medicine and Science in Phoenix. He is currently a Senior Associate Consultant at Mayo Clinic Hospital and has previously served as an Assistant Clinical Professor at the University of Mississippi Medical Center. His areas of expertise include hematopoietic stem cell transplantation, chronic lymphoid leukemia, histiocytic and dendritic cell neoplasms, lymphoma, and CAR-T cell therapy. Dr. Hilal has published multiple papers in prominent journals, contributing to the understanding of conditions such as Richter transformation, clinical trial enrollment disparities, and therapies for mantle cell lymphoma and B-cell ALL.

The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD
The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that l

Substandard control arms question some new cancer drugs' utility - STAT
The rapid pace of new cancer drugs approved by the FDA, 16 in 2018 alone, is - on the surface - good news for people with cancer.